Stuart Mealing

Stuart Mealing

Auto-generated profile, based on publicly available information

Stuart Mealing

York Health Economics Consortium, University of York, York, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
WRWilliam Rickets
William Rickets
KLKelvin Kar Wing Lau
Kelvin Kar Wing Lau
VPVicki Pollit
Vicki Pollit
SMStuart Mealing
Stuart Mealing
CLCatherine Leonard
Catherine Leonard
UNUmamamaheswar Babu Naidu
Umamamaheswar Babu Naidu
Introduction Lung cancer is accountable for 35 000 deaths annually, and prognosis is improved when the cancer is diagnosed early. CT-guided biopsy (transthoracic needle aspiration, TTNA) and electromagnetic navigation bronchoscopy (ENB) can be used to investigate indeterminate pulmonary nodules if the patient is unfit for surgery. However, there is a paucity of clinical and health economic evidence that directly compares ENB with TTNA in this population group. This cost-effectiveness study aimed to explore potential scenarios whereby ENB may be considered cost-effective when compared with TTNA. Methods A cohort decision analytic model was developed using a UK National Health Service perspective. ENB was assumed to have equal sensitivity to TTNA at 82%. Lifetime costs and quality-adjusted life-year (QALY) gain were calculated to estimate the net monetary benefit at a £20 000 per QALY threshold. Sensitivity analyses were used to explore scenarios where ENB could be considered a cost-effective intervention. Results Under the assumption that ENB has equal efficacy to TTNA, ENB was found to be dominant (less costly and more effective) when compared with TTNA, due to having a reduced risk and cost of adverse events. This conclusion was most sensitive to changes in the cost of intervention, estimates of effectiveness and adverse event rates. Discussion ENB is expected to be cost-effective when the likelihood of an accurate diagnosis is equal to (or better than) TTNA, which may occur in certain subgroups of patients in whom TTNA is unlikely to accurately diagnose malignancy or when an experienced practitioner achieves a high accuracy with ENB.

2 June 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
MFMaria Hee Jung Park Frausing
Maria Hee Jung Park Frausing
JJJens Brock Johansen
Jens Brock Johansen
DADaniela Afonso
Daniela Afonso
OJOle Dan Jørgensen
Ole Dan Jørgensen
TOThomas Olsen
Thomas Olsen
MKMads Brix Kronborg
Mads Brix Kronborg
Use of an absorbable antibacterial envelope during implantation prevents cardiac implantable electronic device infections in patients with a moderate-to-high infection risk. Previous studies demonstrated that an envelope is cost-effective in high-risk patients within German, Italian, and English healthcare systems, but these analyses were based on limited data and may not be generalizable to other healthcare settings. A previously published decision-tree-based cost-effectiveness model was used to compare the costs per quality-adjusted life year (QALY) associated with adjunctive use of an antibacterial envelope for infection prevention compared to standard-of-care intravenous antibiotics. The model was adapted using data from a Danish observational two-centre cohort study that investigated infection-risk patients undergoing cardiac resynchronization therapy (CRT) reoperations with and without an antibacterial envelope (n = 1943). We assumed a cost-effectiveness threshold of €34 125/QALY gained, based on the upper threshold used by the National Institute for Health and Care Excellence (£30 000). An antibacterial envelope was associated with an incremental cost-effectiveness ratio (ICER) of €12 022 per QALY in patients undergoing CRT reoperations, thus indicating that the envelope is cost-effective when compared with standard of care. A separate analysis stratified by device type showed ICERS of €6227 (CRT defibrillator) and €29 177 (CRT pacemaker) per QALY gained. Cost-effectiveness ratios were favourable for patients undergoing CRT reoperations in the Danish healthcare system, and thus are in line with previous studies. Results from this study can contribute to making the technology available to Danish patients and align preventive efforts in the pacemaker and ICD area. CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy (-P, pacemaker; -D, defibrillator); ICER, incremental cost-effectiveness ratio; HR, hazard ratio; IQR, interquartile range; QALY, quality-adjusted life year.

1 February 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
Derek ManasDerek Manas
Derek Manas
JBJon K. Bell
Jon K. Bell
SMStuart Mealing
Stuart Mealing
HDHeather Davies
Heather Davies
HBHannah Baker
Hannah Baker
RHRichard A. Hubner
Richard A. Hubner

2 May 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
SHSam Harper
Sam Harper
LGLukasz Grodzicki
Lukasz Grodzicki
SMStuart Mealing
Stuart Mealing
LGLiz Gemmill
Liz Gemmill
PGPaul J. Goldsmith
Paul J. Goldsmith
AAAhmed R. Ahmed
Ahmed R. Ahmed
Gastro-esophageal reflux disease (GERD) is a common, chronic gastrointestinal condition characterized by heartburn, chest pain, regurgitation, and bloating. Current standard of care includes chroni...

1 January 2021 in Journal of Medical Economics
Verified
Journal Article
Open access
RMRichard Mattock
Richard Mattock
IGIlana Gibbons
Ilana Gibbons
JMJoe William Edward Moss
Joe William Edward Moss
SMStuart Mealing
Stuart Mealing
NLNathalie Largeron
Nathalie Largeron
FAFabián P. Alvarez
Fabián P. Alvarez
High dose trivalent influenza vaccine (HD TIV) and adjuvant TIV (aTIV) have been developed specifically for adults aged 65 and older (65+) who are at high risk of life-threatening complications. Ho...

7 December 2022 in Current Medical Research and Opinion
Verified
Journal Article
Open access
HBHannah Baker
Hannah Baker
BABrooke Avey
Brooke Avey
LRLine Overbeck Rethmeier
Line Overbeck Rethmeier
SMStuart Mealing
Stuart Mealing
MBMarie Lynge Buchter
Marie Lynge Buchter
NTNikesh Thiruchelvam
Nikesh Thiruchelvam
To estimate the cost-effectiveness of single-use hydrophilic-coated intermittent catheters (HCICs) versus single-use uncoated intermittent catheters (UICs) for urinary catheterization.The evaluatio...